Pharnext Announces €20.5 Million Bond Loan
Pharnext SA (Paris:ALPHA) (FR0011191287 - ALPHA), a biopharmaceutical company pioneering a new approach to the development of innovative drug combinations based on big data genomics and artificial intelligence, today announced a financing of up to €20 million through a bond loan with IPF Partners, one of the top providers of alternative financings in the healthcare sector.
“This financing with IPF Partners, in combination with the private placement announced earlier this year, strengthens our financial position and enables us to continue advancing the clinical development and commercial preparation for our innovative drug combinations,” said Prof. Daniel Cohen, M.D., Ph.D., Co-Founder and Chief Executive Officer of Pharnext. “We are grateful for the continued support from our shareholders and financial partners, and we look forward to reporting top-line results from our Phase 3 trial of PXT3003 in Charcot-Marie-Tooth disease type 1A later this year.”
The financing consists of three tranches of bonds with an annual interest rate of EURIBOR+11%. The first tranche of €11.5 million will be issued on June 30, 2018 at the latest, the second tranche of €3.5 million will be issued on July 30, 2018 at the latest and the third tranche of €5 million could be issued at Pharnext’s will and following top-line results from Pharnext’s ongoing pivotal Phase 3 trial of PXT3003, its lead drug candidate for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A), expected in the second half of 2018.
Additionaly, a line of convertible bonds will be also issued with Yorkville Advidors for up to €0.5 million in convertible securities, with a maturity date of one year following their date of issue.
The transaction closed today concludes a series of successive financings for Pharnext which began in April 2018, for total proceeds of €36.5 million.
CHARACTERISTICS OF THE PRIVATE PLACEMENT
IPF Partners. The bonds have been issued in accordance with the approval of the Board of Directors implemented according to the Eighth Resolution of the Shareholders’ Meeting of June 28, 2017 (the “Shareholders’ Meeting”), without pre-emptive subscription rights, to the company IPF Fund I SCA, SICAV FIS et IPF Fund II SCA.
A total of 20,000,000 bonds could be issued via private placement, with a price of each equal to €1, and each comprising an ordinary warrant (“Warrant”). Warrants entitle to subscribe a total of 574.372 ordinary shares for the two firsts tranches and 53.968 ordinary shares for the third tranche. Such total of new shares will be entirely assimilated into existing Pharnext shares with an exercise price equal to the volume-weighted average price of an ordinary share of Pharnext on Euronext Paris for the last three days prior to the date of issuance of each tranche minus a five (5) percent discount and will represent approximately 4.81% of the number of outstanding shares in the event of their exercise by IPF. The Warrants may be exercised until July 31, 2026.
YorkVille. Convertible Bonds (“CB”) has been issued in accordance with the approval of the Board of Directors implemented according to the Eighth Resolution of the Shareholders’ Meeting, without pre-emptive subscription rights, to YA II PN, LTD, an investment funds managed by a portfolio management company Yorkville Advisors Global, LP. A total of 50 CB will be issued, each with a par value of €10,000, representing a total aggregate nominal amount of €500,000 and will be subscribed at 98% of par. The convertible bonds have a maturity of 12 months from their date of issue. The CB holder may convert all or any of the CB into a number of ordinary shares equal to the corresponding aggregate principal amount divided by 92% of the lowest daily volume weighted average price over the 10 trading days prior to each conversion date. The CB will not be listed or admitted for trading on the Euronext Growth Paris market. Trading Days during which the CB holder has sold any share of Pharnext in the market will be excluded from the 10 trading days preceding the Conversion Date.
Pursuant to Article 211-3 of the AMF (Autorité des Marchés Financiers) General Regulations, it should be noted that neither of the above-mentioned issues has resulted or will result in the drafting of a prospectus submitted to the AMF for approval.
Pharnext is an advanced clinical-stage biopharmaceutical company developing novel therapeutics for orphan and common neurodegenerative diseases that currently lack curative and/or disease-modifying treatments. Pharnext has two lead products in clinical development. PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. The results of this trial are expected in the second half of 2018. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext has developed a new drug discovery paradigm based on big genomic data and artificial intelligence: PLEOTHERAPY™. The Company identifies and develops synergic combinations of drugs called PLEODRUG™ offering several key advantages: efficacy, safety and robust intellectual property. The Company was founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics and is supported by a world-class scientific team.
Pharnext is listed on Euronext Growth Stock Exchange in Paris (ISIN
For more information, visit http://www.pharnext.com/
IPF Partners is a leading alternative financing provider focused on the healthcare sector with over €200m under management. IPF invests directly in emerging pharma/biotech, medtech and diagnostics companies. Founded in 2011 by a seasoned multi-disciplinary team combining over fifty years of finance and investment and over thirty years of healthcare experience, IPF is providing bespoke, long-term financing.
For more information visit www.ipfpartners.com.
This press release has been issued to fulfil Pharnext's permanent reporting obligations. It does not constitute a public offering, subscription offering or a solicitation in view of a public offering.
François Chamoun, +33 (0)1 41 09 22 30
Financial Communication (France)
Stéphane Ruiz, +33 (0)1 56 88 11 15
Investor Relations (U.S.)
Stern Investor Relations, Inc.
Matthew Shinseki, +1 212 362 1200
Investor Relations (Europe)
MC Services AG
Anne Hennecke, +49 211 529252 22
Media Relations (Europe)
Bruno Arabian, +33 (0)1 81 70 96 30
Media Relations (U.S.)
Kate L. Barrette, +1 212 223 0561
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Results of the MSCI 2019 Market Classification Review25.6.2019 22:15:00 CEST | Pressemelding
MSCI Inc. (NYSE:MSCI), a leading provider of critical decision support tools and services for the global investment community, announces today that it will reclassify the MSCI Kuwait Index to Emerging Markets status, subject to omnibus account structures and same National Investor Number (NIN) cross trades being made available for international institutional investors before the end of November 2019. MSCI will communicate its final decision by December 31, 2019. “Kuwait’s Market Development Project has set the path for the seamless implementation of numerous regulatory and operational enhancements in the Kuwaiti equity market. These enhancements have significantly increased the accessibility level of the Kuwaiti equity market for international institutional investors and resulted in broad positive feedback from these investors on our reclassification proposal,” said Sebastien Lieblich, Global Head of Equity Solutions and Chairman of the MSCI Equity Index Committee. Mr. Lieblich added,
I Squared Capital to Sell Cube Hydro to Ontario Power Generation25.6.2019 19:41:00 CEST | Pressemelding
I Squared Capital, through its ISQ Global Infrastructure Fund I, announced today that it has reached an agreement to sell its hydropower platform, Cube Hydro Partners and its affiliate, Helix Partners (taken together, Cube Hydro), to Ontario Power Generation (OPG) through its U.S. hydroelectric platform. Cube Hydro owns 385 megawatts of hydro capacity on ten river systems in five states, with 19 small to mid-sized, run-of-the-river and peaking hydro plants. “This is the third portfolio company realization in the last twelve months based on the I Squared Capital platform approach, with a total of over $2.8 billion in realized enterprise value,” said Sadek Wahba, Chairman and Managing Partner of I Squared Capital. The other two platforms developed and recently sold by I Squared Capital include Lincoln Clean Energy (a leading onshore wind developer in the U.S. with 800 megawatts) to Ørsted, and Amplus Solar (the preeminent provider of rooftop solar systems for the Indian commercial and in
AerSale Acquires Qwest Air Parts, Inc. to Expand Airframe Parts Sales25.6.2019 19:03:00 CEST | Pressemelding
AerSale ®, a global supplier of aircraft, engines, used serviceable material (USM), and maintenance, repair, and overhaul (MRO) services, announced today it has acquired aircraft parts distributor Qwest Air Parts, Inc. Based in Memphis, Tennessee, Qwest is a recognized leader in aircraft dismantlement and the refurbishment and resale of USM. Qwest has disassembled over 200 aircraft, offers 24/7 AOG service, and operates a teardown facility in Crestview, Florida. Gary Jones, Qwest’s founder, President and CEO, will continue to lead Qwest, which will operate as a stand-alone independent subsidiary of AerSale. The acquisition of Qwest will add scale and reach to AerSale’s already significant airframe USM offerings. Furthermore, Qwest’s recently certified repair station, Q2 Aviation LLC, will supplement AerSale’s growing MRO platform. “As a proven leader in aircraft parts distribution, Qwest is an optimal partner to help further expand our large inventory of high-demand USM, which we cost-
IHS Markit to Integrate Cappitech Technology In SFTR Reporting Solution25.6.2019 16:23:00 CEST | Pressemelding
Cappitech, a leading provider of regulatory reporting and intelligence solutions for the financial services industry and IHS Markit, a world leader in critical information, analytics and solutions, today announced an alliance to deliver the IHS Markit Securities Financing Transactions Regulation (SFTR) solution. The IHS Markit SFTR solution will integrate Cappitech’s award-winning platform CapptivateTM to offer a best-of-breed solution that will meet the industry’s SFTR trade reporting needs by automating and streamlining transaction reporting to trade repositories for all securities finance instruments. It will also support out-of-the-box MiFID II reporting for additional instruments that will be in scope when SFTR goes live. Pierre Khemdoudi, Managing Director & Global Co-Head of Equities, Data and Analytics at IHS Markit, said: “We look forward to leveraging Cappitech’s technology to deliver a regulatory reporting solution that can help manage the comprehensive requirements of SFTR.
Modern Governance 3.0: Modern Governance Extends Beyond the Boardroom to Allow Secure Sharing of Files and Collaboration with Auditors, Regulators and Other Third Parties25.6.2019 13:00:00 CEST | Pressemelding
In its next major extension to support modern governance, Diligent announced today the launch of Secure File Sharing and Secure Meeting Workflow applications, as part of the Diligent Governance Cloud. These groundbreaking applications enable completely secure collaboration not only between board members and executives, but also reaching beyond the boardroom including auditors, regulators and other key third party stakeholders. This significantly raises the bar on security and information governance for organizations operating in this digital, mobile and social era. In today’s fast-paced world, threats come at light speed – from every angle. Leading organizations must set increasingly higher standards to protect against cyber attacks and leaks, while at the same time work collaboratively with more outside parties. Even competent leaders can have blind spots when it comes to the handling of highly sensitive files, specifically in preparation for a board meeting, sharing documents haphaza
Transphorm Strengthens 900 V GaN Portfolio with Second FET25.6.2019 13:00:00 CEST | Pressemelding
Transphorm Inc.—the leader in the design and manufacturing of the highest reliability high-voltage (HV) Gallium Nitride (GaN) semiconductors—today introduced its second 900 V FET, the Gen III TP90H050WS, enhancing the industry’s only 900 V GaN product line. These devices now enable three-phase industrial systems and higher voltage automotive electronics to leverage GaN’s speed, efficiency and power density. Further, the new FET’s platform is based on Transphorm’s 650 V predecessor, the only JEDEC- and AEC-Q101-qualified HV GaN technology. As such, system developers can design with confidence in its quality and reliability. The TP90H050WS has a typical on-resistance of 50 mOhm with a 1000 V transient rating, offered in a standard TO-247 package. The TP90H050WS can reach power levels of 8 kW in a typical half bridge while maintaining greater than 99 percent efficiencies. Its figures of merit for Ron*Qoss (resonant switching topologies) and Ron*Qrr (hard switching bridge topologies) are t